Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
Open Access
- 1 June 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (11), 3987
- https://doi.org/10.3390/ijms21113987
Abstract
In recent years, molecular characterization and management of patients with systemic mastocytosis (SM) have greatly benefited from the application of advanced technologies. Highly sensitive and accurate assays for KIT D816V mutation detection and quantification have allowed the switch to non-invasive peripheral blood testing for patient screening; allele burden has prognostic implications and may be used to monitor therapeutic efficacy. Progress in genetic profiling of KIT, together with the use of next-generation sequencing panels for the characterization of associated gene mutations, have allowed the stratification of patients into three subgroups differing in terms of pathogenesis and prognosis: (i) patients with mast cell-restricted KIT D816V; (ii) patients with multilineage KIT D816V-involvement; (iii) patients with “multi-mutated disease”. Thanks to these findings, new prognostic scoring systems combining clinical and molecular data have been developed. Finally, non-genetic SETD2 histone methyltransferase loss of function has recently been identified in advanced SM. Assessment of SETD2 protein levels and activity might provide prognostic information and has opened new research avenues exploring alternative targeted therapeutic strategies. This review discusses how progress in recent years has rapidly complemented previous knowledge improving the molecular characterization of SM, and how this has the potential to impact on patient diagnosis and management.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (23001)
This publication has 128 references indexed in Scilit:
- Pak and Rac GTPases promote oncogenic KIT–induced neoplasmsJCI Insight, 2013
- Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcriptionNucleic Acids Research, 2013
- mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cellsBlood, 2011
- Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic MastocytosisThe American Journal of Pathology, 2011
- Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR AssayThe Journal of Molecular Diagnostics, 2011
- Mast cell homeostasis and the JAK–STAT pathwayGenes & Immunity, 2010
- Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascadeBlood, 2008
- Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylationThe EMBO Journal, 2007
- Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor SignalingMolecular and Cellular Biology, 2007
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998